# Complete Metadata for Mitochondrial Support Papers

All papers added to references.bib with full bibliographic information.

---

## 1. Forsyth et al. (1999) - NADH RCT

**Citation Key:** `Forsyth1999NADH`

**Full Citation:**
Forsyth LM, Preuss HG, MacDowell AL, Chiazze L, Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol. 1999 Feb;82(2):185-91.

**Identifiers:**
- DOI: 10.1016/S1081-1206(10)62595-1
- PMID: 10071523
- URL: https://pubmed.ncbi.nlm.nih.gov/10071523/

**Study Design:**
Randomized, double-blind, placebo-controlled crossover study

**Sample Size:** n=26 ME/CFS patients

**Intervention:** 10 mg NADH daily for 4 weeks (with 4-week washout)

**Results:**
- 8 of 26 (31%) responded favorably to NADH
- 2 of 26 (8%) responded to placebo
- No severe adverse effects

**Conclusion:**
NADH may be a valuable adjunctive therapy in CFS management

**Certainty:** HIGH (well-designed RCT, peer-reviewed)

---

## 2. Santaella et al. (2004) - NADH vs Conventional Therapy

**Citation Key:** `Santaella2004NADH`

**Full Citation:**
Santaella ML, Font I, Disdier OM. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome. P R Health Sci J. 2004 Jun;23(2):89-93.

**Identifiers:**
- PMID: 15377055
- URL: https://pubmed.ncbi.nlm.nih.gov/15377055/

**Study Design:**
Randomized trial comparing NADH to conventional therapy (nutritional supplements + psychological therapy)

**Sample Size:** n=31 ME/CFS patients

**Duration:** 24 months

**Results:**
- NADH group: dramatic reduction in symptom score in first trimester (p < 0.001)
- Subsequent trimesters: similar outcomes between NADH and conventional therapy groups
- Initial benefit not sustained long-term

**Conclusion:**
NADH showed effectiveness over conventional treatment in first trimester only; larger studies needed

**Certainty:** MEDIUM (negative/mixed result, active control comparison rather than placebo)

---

## 3. Teitelbaum et al. (2006) - D-Ribose Pilot Study

**Citation Key:** `Teitelbaum2006ribose`

**Full Citation:**
Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006 Nov;12(9):857-62.

**Identifiers:**
- DOI: 10.1089/acm.2006.12.857
- PMID: 17109576
- URL: https://pubmed.ncbi.nlm.nih.gov/17109576/

**Study Design:**
Open-label pilot study

**Sample Size:** n=41 patients with fibromyalgia and/or CFS

**Intervention:** 5 g D-ribose three times daily (total 280 g)

**Results:**
- Significant improvement in all five VAS categories:
  - Energy
  - Sleep
  - Mental clarity
  - Pain intensity
  - Well-being
- Well-tolerated
- Improved global patient assessment

**Conclusion:**
D-ribose significantly reduced clinical symptoms in FMS/CFS patients

**Certainty:** MEDIUM (open-label, no placebo control, but multiple positive outcomes)

---

## 4. Plioplys & Plioplys (1995) - Carnitine Levels in CFS

**Citation Key:** `Plioplys1995carnitine`

**Full Citation:**
Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 1995;32(3):132-8.

**Identifiers:**
- DOI: 10.1159/000119226
- PMID: 8544970
- URL: https://pubmed.ncbi.nlm.nih.gov/8544970/

**Study Design:**
Observational/cross-sectional study

**Sample Size:** n=35 CFS patients (27 females, 8 males)

**Results:**
- CFS patients have significantly lower serum levels:
  - Total carnitine (lower)
  - Free carnitine (lower)
  - Acylcarnitine (lower)
- Statistically significant correlation between higher serum carnitine and better functional capacity
- Findings suggest mitochondrial dysfunction contributing to fatigue

**Conclusion:**
Carnitine deficiency may contribute to CFS symptomatology; correlation with functional capacity supports causal role

**Certainty:** HIGH (foundational biomarker study, findings replicated by others)

---

## 5. Plioplys & Plioplys (1997) - L-Carnitine Treatment

**Citation Key:** `Plioplys1997carnitineTreatment`

**Full Citation:**
Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology. 1997;35(1):16-23.

**Identifiers:**
- DOI: 10.1159/000119325
- PMID: 9018019
- URL: https://pubmed.ncbi.nlm.nih.gov/9018019/

**Study Design:**
Treatment study (appears open-label based on available information)

**Intervention:** L-carnitine 3 g/day for 8 weeks (also studied amantadine separately)

**Results:**
- Statistically significant clinical improvement in 12 of 18 studied parameters
- L-carnitine safe and well-tolerated
- Improved clinical status of CFS patients

**Conclusion:**
L-carnitine is a safe, well-tolerated medicine that improves clinical status in CFS

**Certainty:** MEDIUM (treatment study with multiple positive outcomes, but study design details limited)

---

## 6. Vermeulen & Scholte (2004) - Acetyl/Propionyl-Carnitine

**Citation Key:** `Vermeulen2004carnitine`

**Full Citation:**
Vermeulen RCW, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004 Mar-Apr;66(2):276-82.

**Identifiers:**
- DOI: 10.1097/01.psy.0000116249.60477.e9
- PMID: 15039515
- URL: https://pubmed.ncbi.nlm.nih.gov/15039515/

**Study Design:**
Open-label, randomized study

**Sample Size:** n=90 CFS patients (3 groups of 30)

**Intervention:**
- Group 1: 2 g/day acetyl-L-carnitine
- Group 2: 2 g/day propionyl-L-carnitine
- Group 3: Combination (both)

**Duration:** 24 weeks

**Results:**
- Acetyl-L-carnitine group: 59% showed considerable improvement
  - Significantly improved mental fatigue (p=0.015)
  - Plasma carnitine changes correlated with clinical improvement
- Propionyl-L-carnitine group: 63% showed considerable improvement
  - Significantly improved general fatigue (p=0.004)
- Combination group: less improvement than individual treatments
- Both improved attention/concentration

**Conclusion:**
Acetyl- and propionyl-carnitine show beneficial effects on fatigue and attention; combination therapy surprisingly less effective

**Certainty:** HIGH (larger sample, randomized, peer-reviewed, statistically significant results, published in reputable journal)

---

## 7. Malaguarnera et al. (2011) - Acetyl-L-Carnitine in Hepatic Encephalopathy

**Citation Key:** `Malaguarnera2011ALCAR`

**Full Citation:**
Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G, Galvano F. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr. 2011 Apr;93(4):799-808.

**Identifiers:**
- DOI: 10.3945/ajcn.110.007393
- PMID: 21310833
- URL: https://pubmed.ncbi.nlm.nih.gov/21310833/

**Study Design:**
Randomized, double-blind, placebo-controlled trial

**Sample Population:** Patients with hepatic encephalopathy (NOT ME/CFS)

**Intervention:** Oral acetyl-L-carnitine

**Results:**
- Reduced fatigue in hepatic encephalopathy patients
- Improved cognitive function
- Demonstrates neuroprotective benefits
- Improved mitochondrial energetics and function

**Conclusion:**
Acetyl-L-carnitine effective for fatigue and cognitive dysfunction in hepatic encephalopathy

**Certainty for ME/CFS:** LOW (not CFS-specific population)
**Certainty for Mechanism:** HIGH (well-designed RCT demonstrating mechanism of action on fatigue/cognition)

**Note:** Included for mechanistic understanding of acetyl-L-carnitine's effects on fatigue and cognitive function, relevant to understanding potential benefits in ME/CFS mitochondrial dysfunction.

---

## Summary Table

| Study | Year | Design | Sample | Supplement | Dose | Key Finding | ME/CFS Certainty |
|-------|------|--------|--------|------------|------|-------------|------------------|
| Forsyth | 1999 | DB-RCT-X | 26 | NADH | 10mg/day | 31% response vs 8% placebo | HIGH |
| Santaella | 2004 | RCT | 31 | NADH | NR | Initial benefit only | MEDIUM |
| Teitelbaum | 2006 | Open-label | 41 | D-Ribose | 15g/day | Multi-domain improvement | MEDIUM |
| Plioplys | 1995 | Observational | 35 | - | - | Low carnitine = biomarker | HIGH |
| Plioplys | 1997 | Treatment | NR | L-Carnitine | 3g/day | 12/18 parameters improved | MEDIUM |
| Vermeulen | 2004 | Open-label RCT | 90 | Acetyl/Propionyl | 2g/day each | 59-63% improvement | HIGH |
| Malaguarnera | 2011 | DB-RCT | NR | Acetyl-L-carnitine | NR | Reduced fatigue/improved cognition | LOW (non-CFS) |

**Legend:**
- DB-RCT: Double-blind randomized controlled trial
- DB-RCT-X: Double-blind RCT with crossover design
- NR: Not reported in abstract/available information

---

## All Citations Successfully Added to references.bib

Location: `/home/nicky/code/health-me-cfs/references.bib`

All seven citations are now available for use in LaTeX documents with standard `\cite{key}` commands.
